News in Brief

ANVISA grants novel food certification for Levagen

By Stephen Daniells

- Last updated on GMT

© Bunyos / Getty Images
© Bunyos / Getty Images

Related tags ANVISA Brazil Palmitolethanolamide

Gencor’s Levagen, a clinically studied form of palmitolethanolamide (PEA), has been granted novel foods certification by Brazil’s National Health Surveillance Agency ANVISA.

The certification allows Gencor to market and sell Levagen as “ANVISA-certified” within Brazil, said the company in a release.

“The ANVISA Novel Food certification opens the Brazilian market for Levagen and strengthens Gencor’s position as an innovator of ingredients that consumers can trust,” ​said R.V. Venkatesh, Gencor’s Managing Director.

“We are very happy to have achieved the certification and will continue to provide ingredients that are well-studied and convey benefits that consumers value.”

Palmitolethanolamide (PEA) was first discovered in 1957 as a component in egg yolk, when egg yolk was being researched for its anti-inflammatory properties. It is a fatty acid amide that helps to stimulate production of endocannabinoids in the body.

PEA is an endogenous compound that is produced by our body as a first responder to pain, stress, inflammation and is used up locally in all tissues. It can be offset and restored when depleted through dietary supplementation.

Related news

Related product